Syed et al. [152] highlighted the potential of fisetin as a therapeutic option for melanoma treatment via the modulation of the WNT/β-catenin signaling pathway, as the increase in endogenous WNT inhibitors DKK1 and WIF was concomitant with the decrease in the expression of coreceptors FZDs/LRP-6 and DVL has been observed in fisetin-treated melanoma cells. Here, LRP6 is linked to melanoma.